Antibe Therapeutics has entered into an exclusive licensing agreement with Kwang Dong Pharmaceutical Co., Ltd. for the development and commercialization of Antibe’s lead drug, ATB-346, in South Korea (the “Region”). Kwang Dong is a major pharmaceutical company in the Region, with net sales in excess of $600 million and over 500 sales representatives. Under the terms of…